Categories AlphaGraphs, Earnings, Health Care
ABBV Earnings: Highlights of AbbVie’s Q2 2022 financial results
Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) has reported double-digit growth in second-quarter adjusted earnings, reflecting an increase in revenues. The company also provided earnings guidance for fiscal 2022.
Total revenues increased 5% year-over-year to $14.6 billion, aided by a strong performance by the immunology and neuroscience segments.
At $3.37 per share, adjusted net income was up 11% year-over-year. Unadjusted profit increased sharply to $924 million or $0.51 per share from $766 million or $0.42 per share in the second quarter of 2021.
Check this space to read management/analysts’ comments on AbbVie’s Q2 2022 earnings
“We delivered another strong quarter with substantial progress for our new products and indications. Importantly, Skyrizi and Rinvoq continued their impressive ramps and are on pace to deliver approximately $7.5 billion in combined annual sales, underscoring their significant potential,” said Richard A. Gonzalez, CEO of AbbVie.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on